Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mari Iida

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Frontiers in Oncology|May 20, 2025
Tumor-associated MerTK promotes a pro-inflammatory microenvironment and enhances immune checkpoint inhibitor response in triple-negative breast cancerBridget E Crossman, Regan L Harmon, Mari Iida, et al.
Carcinogenesis|May 3, 2003
Changes in global gene and protein expression during early mouse liver carcinogenesis induced by non-genotoxic model carcinogens oxazepam and Wyeth-14,643Mari Iida, Colleen H Anna, Jennifer Hartis, et al.
Molecular Cancer Therapeutics|July 17, 2016
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to CetuximabMari Iida, Harsh Bahrar, Toni M Brand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2015
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell CarcinomaToni M Brand, Mari Iida, Andrew P Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2018
Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell CarcinomaToni M Brand, Mari Iida, Andrew P Stein, et al.
Cancer Biology & Therapy|June 25, 2013
Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancerIchiro Kawada, Rifat Hasina, Frances E Lennon, et al.
Molecular Cancer Therapeutics|August 11, 2018
MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting AgentsNellie K McDaniel, Christopher T Cummings, Mari Iida, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2020
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck CancerNellie K McDaniel, Mari Iida, Kwangok P Nickel, et al.
Journal of Clinical Medicine|October 26, 2024
From Bench to Bedside: A Team's Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell CarcinomaBridget E Crossman, Regan L Harmon, Kourtney L Kostecki, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Frontiers in Oncology|May 20, 2025
Tumor-associated MerTK promotes a pro-inflammatory microenvironment and enhances immune checkpoint inhibitor response in triple-negative breast cancerBridget E Crossman, Regan L Harmon, Mari Iida, et al.
Carcinogenesis|May 3, 2003
Changes in global gene and protein expression during early mouse liver carcinogenesis induced by non-genotoxic model carcinogens oxazepam and Wyeth-14,643Mari Iida, Colleen H Anna, Jennifer Hartis, et al.
Molecular Cancer Therapeutics|July 17, 2016
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to CetuximabMari Iida, Harsh Bahrar, Toni M Brand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2015
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell CarcinomaToni M Brand, Mari Iida, Andrew P Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2018
Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell CarcinomaToni M Brand, Mari Iida, Andrew P Stein, et al.
Cancer Biology & Therapy|June 25, 2013
Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancerIchiro Kawada, Rifat Hasina, Frances E Lennon, et al.
Molecular Cancer Therapeutics|August 11, 2018
MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting AgentsNellie K McDaniel, Christopher T Cummings, Mari Iida, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2020
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck CancerNellie K McDaniel, Mari Iida, Kwangok P Nickel, et al.
Journal of Clinical Medicine|October 26, 2024
From Bench to Bedside: A Team's Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell CarcinomaBridget E Crossman, Regan L Harmon, Kourtney L Kostecki, et al.
Pageof 6